Severe acute respiratory syndrome caused by COVID-19 is associated with a hypercoagulable state and an increased risk of thrombotic events. Since the beginning of the pandemic, thromboprophylaxis has been recommended for these patients despite initial insufficient evidence. In the fall of 2020, an observational study was published confirming the beneficial effect of enoxaparin on reducing mortality and the risk of ICU admission in patients with severe COVID-19.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
